Manuel Salto‐Tellez
YOU?
Author Swipe
View article: 222P Developing an integrated multimodal platform for the POETIC breast cancer trial
222P Developing an integrated multimodal platform for the POETIC breast cancer trial Open
View article: 226P In-house and commercial platforms for integrated discovery and diagnostics in pathology
226P In-house and commercial platforms for integrated discovery and diagnostics in pathology Open
View article: ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)
ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI) Open
View article: Beyond tumour mutational burden: Determinants of response to combination radiation/immunotherapy in Muscle-Invasive Bladder Cancer (MIBC)
Beyond tumour mutational burden: Determinants of response to combination radiation/immunotherapy in Muscle-Invasive Bladder Cancer (MIBC) Open
View article: 413P Mismatch repair deficiency (MMRd) in esophagogastric adenocarcinoma (ADC) following chemotherapy for resectable disease: Correlation with survival and recurrence patterns from ST03 and OE05 trials
413P Mismatch repair deficiency (MMRd) in esophagogastric adenocarcinoma (ADC) following chemotherapy for resectable disease: Correlation with survival and recurrence patterns from ST03 and OE05 trials Open
View article: Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology
Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology Open
Clinical decision-making in oncology is complex, requiring the integration of multimodal data and multidomain expertise. We developed and evaluated an autonomous clinical artificial intelligence (AI) agent leveraging GPT-4 with multimodal …
View article: Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
MANIFEST Consortium List of Authors
View article: Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Summary:Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-chan…
View article: Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Notable large-scale immuno-oncology consortia formed in the recent era.
View article: A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) Open
Background Targeting RAS mutant (MT) colorectal cancer (CRC) remains a difficult challenge, mainly due to the pervasiveness of RAS/MEK-mediated feedback loops. Preclinical studies identified MET/STAT3 as an important mediator of resistance…
View article: A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers Open
Background Single-agent MEK1/2 inhibition has been disappointing in clinical trials targeting RAS mutant (MT) cancers, probably due to upstream receptor activation, resulting in resistance. We previously found that dual c-MET/MEK1/2 inhibi…
View article: Implementing digital pathology: qualitative and financial insights from eight leading European laboratories
Implementing digital pathology: qualitative and financial insights from eight leading European laboratories Open
Digital Pathology (DP) revolutionizes the diagnostic workflow. Digitized scanned slides enhance operational efficiency by facilitating remote access, slide storage, reporting and automated AI image analysis, and enabling collaboration and …
View article: 40P MANIFEST: A multiomic profiling platform for immuno-oncology biomarker discovery
40P MANIFEST: A multiomic profiling platform for immuno-oncology biomarker discovery Open
View article: Supplementary Table 2 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 2 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 2
View article: Supplementary Figure 5 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Figure 5 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Figure 5
View article: S:CORT members list from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
S:CORT members list from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
S:CORT members list
View article: Supplementary Table 4 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 4 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 4
View article: Supplementary Figure 5 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Figure 5 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Figure 5
View article: Supplementary Table 6 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 6 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 6
View article: Supplementary Table 1 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 1 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 1
View article: Supplementary Figure 3 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Figure 3 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Figure 3
View article: Data from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Data from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Response to neoadjuvant radiotherapy (RT) in rectal cancer has been associated with immune and stromal features that are captured by transcriptional signatures. However, how such associations perform across different chemoradiotherapy regi…
View article: Supplementary Figure 4 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Figure 4 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Figure 4
View article: Supplementary Table 3 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 3 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 3
View article: Supplementary Table 1 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 1 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 1
View article: Supplementary Material from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Material from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Material
View article: Supplementary Table 5 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 5 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 5
View article: Supplementary Table 4 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Table 4 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Table 4
View article: Supplementary Figure 2 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Figure 2 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Figure 2
View article: Supplementary Figure 1 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Supplementary Figure 1 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures Open
Supplementary Figure 1